Close

Intellia Therapeutics’ Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/19/2024

1. NFLX
2. TSM
3. ISRG
4. INFY
5. SNV
6. TSLA
7. SPY
8. SMCI
9. BX
10. AAPL


Go back to Intellia Therapeutics’ Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis
(NASDAQ: NTLA) Delayed: 21.36 +0.04 (0.19%)
Previous Close $21.32    52 Week High $30.40 
Open $21.22    52 Week Low $11.86 
Day High $21.56    P/E N/A 
Day Low $20.78    EPS $0.00 
Volume 770,150